Adalimumab BS MA (adalimumab biosimilar) / Mochida, LG Chem, Daewoong Pharma - LARVOL DELTA

Data Hazards as An Ethical Toolkit for Neuroscience. (PubMed, Neuroethics) - "The Data Hazards framework (Zelenka, Di Cara, & Contributors, 2024) is intended to encourage thinking about the ethical implications of data science projects...We demonstrate how the hazard labels can be applied to one of our own projects, on the computational modelling of postsynaptic mechanisms. The online version contains supplementary material available at 10.1007/s12152-024-09580-3."

Journal

Improved injection site reactions after switching from adalimumab reference to adalimumab biosimilar LBAL for ulcerative colitis: A case report. (PubMed, Medicine (Baltimore)) - "We showed the efficacy and safety of ADA biosimilar LBAL as an alternative to ADA reference, which caused injection site reactions. Changing from ADA reference to ADA biosimilar because of adverse events may be an option that needs careful observation, considering that the originator and the biosimilar are not exactly the same."

Journal • Allergy • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Oncology • Pruritus • Ulcerative Colitis • TNFA

Adalimumab originator and biosimilars in global inflammatory bowel disease treatment (AGW-GESA 2024) - "Products marketed in Australia, namely Humira, Yuflyma, Idacio, Hyrimoz, Hadlima, Abrilada, and Amgevita, as well as Exemptia in India, provide the most extensive support. Adalimumab products exhibit variations in formulations and associated support programs across different countries. Among the four products offering high-concentration citrate-free formulations, Humira and Xelenka offer a wide range of dosages for different indications. Meanwhile, Xelenka, Yuflyma, and Ardalicip provide the longest room temperature shelf lives, which is favourable for travellers."

Clinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Pediatrics

Daewoong Pharm launches Humira biosimilar targeting autoimmune disease market (Korea Biomedical Review) - "Daewoong Pharmaceutical said on Monday that it launched Xelenka, LG Chem's biosimilar referencing Humira (active ingredient: adalimumab), in Korea. Approved by the Ministry of Food and Drug Safety (MFDS) in December last year, Xelenka marks the third biosimilar of Humira introduced in Korea. Under a distributor agreement between Daewoong Pharmaceutical and LG Chem, LG Chem will supply Xelenka to Daewoong Pharmaceutical, which will handle domestic sales and marketing."

Biosimilar launch • Crohn's disease • Immunology • Inflammatory Bowel Disease • Psoriasis • Rheumatoid Arthritis • Ulcerative Colitis

Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®). (PubMed, Anim Cells Syst (Seoul)) - "As indicated, this extensive analytical characterization and functional comparison assessment showed that LBAL was similar to Humira®, with minor differences of no clinical relevance. Taken together, our comparative assessment of physicochemical and biological attributes demonstrated that LBAL is structurally and functionally very similar to Humira®, supporting the biosimilarity of clinical efficacy and safety."

Journal • Oncology • TNFA

Comparison of the efficacy and safety of LBAL, a candidate adalimumab biosimilar, and adalimumab reference product in patients with active rheumatoid arthritis inadequately responding to methotrexate: a 52-week phase III randomised study. (PubMed, Clin Exp Rheumatol) - "LBAL was equivalent in efficacy and comparable in safety, including immunogenicity, to ADL. Switching from ADL to LBAL did not impact on efficacy and safety."

Clinical • Journal • P3 data • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - P3; N=383; Completed; Sponsor: LG Life Sciences; Active, not recruiting ➔ Completed

Clinical • Trial completion • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

"@KMyersDPT @chadcookpt @mroll121 @BridgetRipaPT @KaylaHolz @ZacharyRethorn @PaulieSalamh @LBallengee @ZacharyRethorn @jafeld @lardinois_kara all are part of the great team making strides in PT Ed Research @Duke_DPT" (@KyleCovPT)

"@JBeneciuk @LBallengee @zachrstearns @ZacharyRethorn @KenTaylorDPT @GiorgioZeppieri @AdamGoode58 @jsharpePT363" (@DukeMSK)

"Mira @LBallesterosM este es uno de los problemas... Y favorece aglomeraciones, lo cual ahora es fatal... Pobre gente caray. No viajes innecesarios 🌟🙌🏽🌟" (@BrendaCrabtreeR)

Clinical and laboratory features of Mycobacterium avium complex infection in comparison with infection, caused by Mycobacterium tuberculosis, in HIV-infected patients (ERS 2019) - "MGM/CL for MAC was positive from: blood, urine and feces - 5 patients (including 3 in combination with sputum and liquid bronchoalveolar lavage (S/LBAL)) - 1st group , S/LBAL solely - 4 patients - 2nd group...8 (53%) were febrile Conclusion. Febrile HIV late presenters should be suspected for "the septic form" of MAC disease; blood, urine and feces being obligatory tested by MGM/CL"

Clinical